Subtype
Malignant Neoplasm of Unknown Primary
CI-CAN-00001150CUPExplore in graph →
4,158 active trials54 approved drugs532 evidence items
- NCIt
- C8566
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001150CUPExplore in graph →
Clinical trials
14,247 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,894)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04286386 | Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam | withdrawn | — | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 15, 2026 | clinicaltrials |
| NCT07365839 | Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma(CLeAR) | withdrawn | Phase 1 | 0 | Virginia Commonwealth UniversityOTHER | 0 | Sep 14, 2026 |
| clinicaltrials |
| NCT06929338 | xDRIVE in Metastatic Colorectal Cancer | withdrawn | — | 0 | First Ascent Biomedical Inc.INDUSTRY | 0 | Sep 2, 2026 | clinicaltrials |
| NCT06990737 | Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck | withdrawn | Phase 2 | 0 | University of California, DavisOTHER | 0 | Aug 31, 2026 | clinicaltrials |
| NCT06982222 | Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Aug 28, 2026 | clinicaltrials |
| NCT05423197 | 89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC | withdrawn | Phase 2 | 0 | Andrei IagaruOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05737615 | PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9 | withdrawn | Phase 1 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Aug 12, 2026 | clinicaltrials |
| NCT06610097 | TNBC Gut Microbiota During Neoadjuvant Treatment | withdrawn | N/A | 0 | Scripps HealthOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07075627 | A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subjects Diagnosed With Small Cell Lung Cancer (SCLC) | withdrawn | — | 0 | Addario Lung Cancer Medical InstituteOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT04273555 | Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging | withdrawn | Phase 1 / Phase 2 | 0 | University of Alabama at BirminghamOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07100925 | A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma | withdrawn | Phase 1 | 0 | Ankyra Therapeutics, IncINDUSTRY | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07136493 | Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07216833 | Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06902246 | Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | University of MiamiOTHER | 0 | Jun 15, 2026 | clinicaltrials |
| NCT03402880 | ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06708936 | KSD-201 Treatment for Advanced Clear Cell Renal Cell Carcinoma: an Early Exploratory Clinical Study | withdrawn | Early Phase 1 | 0 | Kousai Bio Co., Ltd.OTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04481204 | New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 4, 2026 | clinicaltrials |
| NCT07134556 | Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC(ADJUNCT) | withdrawn | Phase 2 | 0 | MedSIROTHER | 0 | May 1, 2026 | clinicaltrials |
| NCT06732258 | Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC | withdrawn | Phase 1 | 0 | Sichuan UniversityOTHER | 0 | Apr 29, 2026 | clinicaltrials |
| NCT07328490 | Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2026 | clinicaltrials |
| NCT02856503 | Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Eli Avisar, MDOTHER | 0 | Apr 17, 2026 | clinicaltrials |
| NCT07284953 | A Novel Haemostatic Agent for Robotic Partial Nephrectomy(PuraBond) | withdrawn | N/A | 0 | The Royal Wolverhampton Hospitals NHS TrustOTHER_GOV | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06229392 | A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer | withdrawn | Phase 1 | 0 | Rush University Medical CenterOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT03868475 | Comparing Vacuum-Assisted Percutaneous Excision to Open Surgical Excision for Borderline or High-Risk Breast Lesions(VAPEX) | withdrawn | N/A | 0 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 0 | Mar 9, 2026 | clinicaltrials |
| NCT05296135 | Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell Cancer(PREDAPT-HNSCC2) | withdrawn | — | 0 | Cofactor Genomics, Inc.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05566223 | CISH Inactivated TILs in the Treatment of NSCLC(CheckCell-2) | withdrawn | Phase 1 / Phase 2 | 0 | Intima Bioscience, Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT06217094 | Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment | withdrawn | Phase 1 | 0 | University of FloridaOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT05312372 | S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC | withdrawn | Phase 1 / Phase 2 | 0 | Institut de Recherches Internationales ServierOTHER | 0 | Feb 17, 2026 | clinicaltrials |
| NCT06585969 | A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer(DISCORDANT) | withdrawn | Phase 3 | 0 | Danish Breast Cancer Cooperative GroupOTHER | 0 | Feb 12, 2026 | clinicaltrials |
| NCT07226102 | Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07283848 | Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT06626256 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Dec 24, 2025 | clinicaltrials |
| NCT06603155 | Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC) | withdrawn | N/A | 0 | Duke UniversityOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05668949 | Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC) | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Dec 17, 2025 | clinicaltrials |
| NCT07084909 | Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC(HARRIER) | withdrawn | Phase 2 / Phase 3 | 0 | Lantheus Medical ImagingINDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
| NCT05845307 | Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck | withdrawn | Early Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Dec 8, 2025 | clinicaltrials |
| NCT06994299 | A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma(PRISM) | withdrawn | Phase 2 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04419181 | Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer | withdrawn | Phase 2 | 0 | University of RochesterOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT06528210 | Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Sep 23, 2025 | clinicaltrials |
| NCT06690281 | A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2025 | clinicaltrials |
| NCT06084689 | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures(EMPIRE) | withdrawn | Phase 2 | 0 | Institut BergoniéOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT06420908 | Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) | withdrawn | N/A | 0 | Hebei Medical University Fourth HospitalOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT06361810 | PSMA Therapy and Immunotherapy in Kidney Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 0 | Aug 19, 2025 | clinicaltrials |
| NCT06762808 | Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 15, 2025 | clinicaltrials |
| NCT07011849 | Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 13, 2025 | clinicaltrials |
| NCT07038915 | STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1 | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 5, 2025 | clinicaltrials |
| NCT06362421 | Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer | withdrawn | — | 0 | Wake Forest University Health SciencesOTHER | 0 | Jul 31, 2025 | clinicaltrials |
| NCT05678205 | A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Artiva Biotherapeutics, Inc.INDUSTRY | 2 | Jul 30, 2025 | clinicaltrials |
| NCT06246786 | Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer) | withdrawn | Early Phase 1 | 0 | Virginia G. KaklamaniOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06086925 | A Window of Opportunity Study of Black Raspberry for Patients With HNSCC | withdrawn | Early Phase 1 | 0 | Mitchell MachtayOTHER | 0 | Jul 11, 2025 | clinicaltrials |
Data updated 14 days agoSource updated Sep 15, 2026source: clinicaltrials